Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-12-19
2010-10-26
Krass, Frederick (Department: 1612)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
07820670
ABSTRACT:
Methods for using 6-aminoimidazo[1,2-b]pyridazine analogs are disclosed herein to treat rho kinase-mediated diseases or rho kinase-mediated conditions, including controlling intraocular pressure and treating glaucoma, are disclosed. Ophthalmic pharmaceutical compositions useful in the treatment of eye diseases such as glaucoma, and additionally useful for controlling intraocular pressure, the compositions comprising an effective amount of 6-aminoimidazo[1,2-b]pyridazine analogs, are disclosed herein.
REFERENCES:
patent: 5798380 (1998-08-01), Kaufman et al.
patent: 6110912 (2000-08-01), Kaufman et al.
patent: 6218410 (2001-04-01), Uehata et al.
patent: 6271224 (2001-08-01), Kapin et al.
patent: 6403590 (2002-06-01), Hellberg et al.
patent: 6451825 (2002-09-01), Uehata et al.
patent: 6579519 (2003-06-01), Maitra et al.
patent: 6586425 (2003-07-01), Kaufman et al.
patent: 6649625 (2003-11-01), Azuma et al.
patent: 6673812 (2004-01-01), Azuma et al.
patent: 6720341 (2004-04-01), Moriyama et al.
patent: 6794398 (2004-09-01), Nakamuta et al.
patent: 2002/0045585 (2002-04-01), Kaufman et al.
patent: 2003/0220376 (2003-11-01), Masferrer et al.
patent: 2007/0049591 (2007-03-01), Pinkerton et al.
patent: 1034793 (2000-09-01), None
patent: 99/23113 (1999-05-01), None
patent: 01/68608 (2001-09-01), None
patent: WO 02/066481 (2002-08-01), None
patent: 02/096318 (2002-12-01), None
patent: 02/100833 (2002-12-01), None
patent: 03/059913 (2003-07-01), None
patent: 03/062227 (2003-07-01), None
patent: 2004/000318 (2003-12-01), None
patent: 2004/009555 (2004-01-01), None
patent: 2004/024717 (2004-03-01), None
patent: 2004/084824 (2004-10-01), None
patent: 2004/085409 (2004-10-01), None
patent: 2007/025090 (2007-03-01), None
US 6,503,924, 01/2003, Azuma et al. (withdrawn)
Bullock, Structural Basis of Inhibitor Specificity of the Human Protooncogene Proviral Insertion Site in Moloney Murine Leukemia Virus (PIM-1) Kinase, J. Med. Chem. vol. 48, 7604-7614, 2005.
Adachi et al., “Studies on Pyrazines. I. The Syntheses of 2,3-Dihydroxypyrazines and Their Derivatives”, Journal of Organic Chemistry, vol. 37(2):221-225, 1972.
Fukiage et al., “Involvement of Phosphorylation of Myosin Phosphatase by ROCK in Trabecular Meshwork and Ciliary Muscle Contraction”, Biochemical and Biophysical Research Communications, vol. 288:296-300, 2001.
Honjo et al., “Effects of Protein Kinase Inhibitor, HA1077, on Intraocular Pressure and Outflow Facility in Rabbit Eyes”, Archives of Ophthalmology, vol. 119:1171-1178, 2001.
Honjo et al., “Effects of Rho-Associated Protein Kinase Inhibitor Y-27632 on Intraocular Pressure and Outflow Facility”, IOVS, vol. 42:137-144, 2001.
Ishizaki et al., “Pharmacological Properties of Y-27632, a Specific Inhibitor of Rho-Associated Kinases”, Molecular Pharmacology, vol. 57:976-983, 2000.
Loge et al., “Rho-kinase Inhibitors: Pharmacomodulations on the Lead Compound Y-32885”, Journal of Enzyme Inhibition and Medicinal Chemistry, vol. 17:381-390, 2002.
Loge et al., “Synthesis and Pharmacological Study of Rho-Kinase Inhibitors: Pharmacomodulations on the Lead Compound Fasudil”, Journal of Enzyme Inhibition and Medicinal Chemistry, vol. 18:127-138, 2003.
Rao et al., “Modulation of Aqueous Humor Outflow Facility by the Rho Kinase-Specific Inhibitor Y-27632”, IOVS, vol. 42:1029-1037, 2001.
Sasaki et al., “Novel and Specific Rho-Kinase Inhibitor, H1152P, Directed Against the Rho-Kinase Involved Pathway”, Cell Biology Molecular Letters, vol. 6(2B):506, 2001.
Sasaki et al., “The Novel and Specific Rho-kinase Inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine as a Probing Molecule for Rho-kinase-involved Pathway”, Pharmacology and Therapeutics, vol. 93:225-232, 2002.
Sato et al., “Studies on Pyrazines. Part 33. Synthesis of 2,3-Diaminopyrazines via [1,2,5]Thiadiazole-[3,4-b] pyrazines”, Journal of Chemical Research, vol. 7:250-251, 1997.
Sato et al., “Studies on Pyrazines; Part 30: Synthesis of Aminopyrazines from Azidopyrazines and Azidopyrazines”, Synthesis, vol. 9:931-934, 1994.
Sato et al., “Studies on Pyrazines 3. A Facile Synthetic Method for 2,3-Diaminopyrazines”, Journal of Organic Chemistry, vol. 43(2):341-343, 1978.
Sato et al., “Studies on Pyrazines. Part 27. A New Deoxidative Nucleophilic Substitution of Pyrazine N-Oxides; Synthesis of Azidopyrazines with Trimethylsilyl Azide”, Journal of the Chemical Society Perkin Trans., vol. 7:885-888, 1994.
Satoh et al., “Pharmacological Profile of Hydroxy Fasudil as a Selective Rho Kinase Inhibitor on Ischemic Brain Damage”, Life Sciences, vol. 69:1441-1453, 2001.
Sharif et al., “Pharmacological and Molecular Biological (RT-PCR) Characterization of Functional TP Prostanoid Receptors in Immortalized Human Non-Pigmented Ciliary Epithelial Cells”, J. Ocular Pharmacology and Therapeutics, vol. 18(2):141-162, 2002.
Sharif et al., “Cloned Human EP Prostanoid Receptor Pharmacology Characterized Using Radioligand Binding Techniques”, Journal of Pharmacy and Pharmacology, vol. 54:539-547, 2002.
Sharif et al., “Pharmacology of [3H]Prostaglandin E1/[3H]Prostaglandin E2 and [3H]Prostaglandin F2a Binding to EP3 and FP Prostaglandin Receptor Binding Sites in Bovine Corpus Luteum: Characterization and Correlation with Functional Data”, Journal of Pharmacology and Experimental Therapeutics, vol. 286:1094-1102, 1998.
Sharif et al., “Affinities, Selectivities, Potencies and Intrinsic Activities of Natural and Synthetic Prostanoids Using Endogenous Receptors: Focus on DP Class Prostanoids”, Journal of Pharmacology and Experimental Therapeutics, vol. 293:321-328, 2000.
Takami et al., “Design and Synthesis of Rho Kinase Inhibitors (I)”, Bioorganic and Medicinal Chemistry, vol. 12:2115-2137, 2004.
Thieme et al., “Mediation of Calcium-Independent Contraction in Trabecular Meshwork Through Protein Kinase C and Rho-A”, IOVS, vol. 41:4240-4246, 2000.
Tian et al., “Effects of Topical -7 on Outflow Facility, Intraocular Pressure and Corneal Thickness in Monkeys”, Archives of Ophthalmology, vol. 122:1171-1177, 2004.
Uehata et al., “Calcium Sensitization of Smooth Muscle Mediated by Rho-associated Protein Kinase in Hypertension”, Nature, vol. 389:990-994, 1997.
Waki et al., “Reduction of Intraocular Pressure by Topical Administration of an Inhibitor of the Rho-associated Protein Kinase”, Current Eye Research, vol. 22(6):470-474, 2001.
Wettschureck et al., “Rho/Rho-kinase Mediated Signaling in Physiology and Pathophysiology”, Journal of Molecular Medicine, vol. 80:629-638, 2002.
Chen Hwang-Hsing
Guo Cheng
Hadden Mark
Hellberg Mark R.
Henderson Alan J.
Alcon Research, Ltd.
Flanigan Mark E.
Krass Frederick
Milligan Adam
LandOfFree
6-aminoimidazo[1,2-b]pyridazine analogs as rho kinase... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 6-aminoimidazo[1,2-b]pyridazine analogs as rho kinase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 6-aminoimidazo[1,2-b]pyridazine analogs as rho kinase... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4224618